U.s. food and drug administration approves bristol myers squibb's breyanzi as a new car t cell therapy for relapsed or refractory mantle cell lymphoma

Princeton, n.j.--(business wire)---- $bmy #breyanzi--u.s. food and drug administration approves bristol myers squibb's breyanzi as a new car t cell therapy for relapsed or refractory mantle cell lymphoma.
CAR Ratings Summary
CAR Quant Ranking